Zdenek Hel1, David Venzon2, Monita Poudyal1, Wen-Po Tsai1, Laura Giuliani1, Ruth Woodward3, Claire Chougnet4, Gene Shearer4, John D. Altman5, David Watkins6, Norbert Bischofberger7, Alashle Abimiku8, Phillip Markham3, James Tartaglia9, 10
& Genoveffa Franchini11
National Cancer Institute, Basic Research Laboratory
, 41/D804, Bethesda, Maryland
20892, USA
2
National Cancer Institute, Biostatistics and Data Management
Section, Bethesda, Maryland 20892,
USA
3
Advanced BioScience Laboratories, Inc.,
Kensington, Maryland 20895, USA
4
National Cancer Institute, Experimental Immunology
Branch, 10/4B17, Bethesda, Maryland
20892, USA
5
Emory University Vaccine Center at Yerkes,
Atlanta, Georgia 30329, USA
6
Wisconsin Regional Primate Research Center,
Madison, Wisconsin 53715, USA
7
Gilead Sciences, Foster City,
California 94404, USA
8
Institute of Human Virology, 725 West
Lombard Street, Baltimore, MD 21201
9
Aventis Pasteur, Ltd., Toronto,
Ontario, Canada M2R 3T4
10
Virogenetics Corporation, Troy,
New York 12180, USA
Correspondence should be addressed to Genoveffa Franchini veffa@helix.nih.gov
